Merit Medical (MMSI) Q2 2026 Earnings Call Transcript
Merit Medical Systems (MMSI) reported Q2 2026 revenue of $418.8 million, up 10% GAAP, and non-GAAP EPS of $1.19. Non-GAAP operating margin was 22.6% and free cash flow $51.9 million. The company raised 2026 revenue guidance to $1.631B-$1.643B and non-GAAP EPS to $4.25-$4.35, and guided Q3 revenue to $408M-$413M.
How this was made
The 30-second read
Why it matters
The call includes multiple quantitative updates: Q2 results, raised 2026 revenue and non-GAAP EPS guidance, and Q3 revenue and non-GAAP EPS ranges, alongside margin drivers and segment-level growth.
Market read
Traders can update models based on the raised full-year 2026 revenue and non-GAAP EPS guidance and the provided Q3 2026 revenue and EPS ranges, while monitoring tariff and recall-related normalization.
What to watch
International trade costs and competitive intensity in vascular access are flagged as ongoing risks, and OEM restocking plus acquisition integration (View Point Medical, C2 CryoBalloon) may introduce execution variability.
Background
Merit Medical Systems held its Q2 2026 earnings call and discussed progress on its Continued Growth Initiative (CGI), product platform performance, and acquisition integration.
Ticker impact
Merit Medical reported Q2 2026 revenue of $418.8M, raised 2026 revenue guidance to $1.631B-$1.643B, and lifted non-GAAP EPS to $4.25-$4.35.
Likely supportive for near-term positioning, with upside bias if Q3 results track the guided $408M-$413M revenue and $0.98-$1.08 non-GAAP EPS.
The article provides multiple forward-looking ranges (2026 and Q3) plus drivers (gross margin expansion, tariff refund, OEM growth, resolved recall), which can re-rate expectations, though some benefits (tariff refund) may be non-recurring.
Market effects
Medical device peers may see read-across on vascular access and oncology expansion execution, plus margin resilience despite tariff uncertainty.
U.S. revenue growth outperformance ($252M, +11% YoY) and Asia-Pacific strength ($166.8M, +7.3% YoY) highlight demand durability across regions.
Tariff cost forecasting uncertainty remains a cross-border risk factor for device supply chains, with MMSI explicitly calling out difficulty predicting timing and impact.
Counterpoint
Some earnings support appears partly one-time (tariff refund) and recall recapture may lag, so the quality of margin and revenue growth could be less durable than the headline guidance implies.
Key entities
- companyMerit Medical Systems
Reported Q2 2026 results and updated 2026 and Q3 guidance, citing margin expansion, OEM growth, and acquisition integration.
- executiveMartha Aronson
CEO who discussed competitive dynamics, product launches, and ongoing M&A evaluation.
- executiveRaul Parra
CFO who addressed tariff forecasting uncertainty and margin drivers.
- acquired companyView Point Medical
Acquisition referenced as contributing to net leverage and integration progress.
